Merck Stock News

Molnupiravir was shown to reduce hospitalisations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness

While vaccines, boosters remain foremost tools in fight against pandemic, experts welcome addition of new oral treatments

Pfizer''s COVID-19 antiviral pill will already have some competition in the US: The Food and Drug Administration has given emergency use authorization for Merck''s Molnupiravir pill.

New Delhi, Dec 23 (IANS) A day after authorising the first anti-viral pill to treat Covid 19, the US Food and Drug Administration on Thursday authorised a second, Mercks Molnupiravir, USA Today reported. The prescription medication, which can be taken at home, is designed to stop the progression of COVID-19 from mild to severe symptoms [] The post FDA authorises Mercks Covid-19 pill that can be taken at home appeared first on Buziness Bytes .

For the second time in as many days, federal regulators on Thursday granted emergency approval to an antiviral pill as a treatment for COVID-19 -- this one from Merck.

The White House dims optimism over the Omicron batter after the US Food and Drug Administration (FDA) approved a pair of pills from Pfizer and Merck

Top 10 Themes For 2022: Part 1 In its comprehensive take of the top 10 themes for 2022, Deutsche Bank''s Luke Templeman asks if covid is the only theme that matters ? He correctly responds that "that is not the right question. In fact, covid is now not so much a theme as it is the backdrop against which most things are evolving in economics, finance, and corporates." So what themes matter in 2022? As part of Deutsche Bank''s look ahead analysis, Templeman, director of the bank''s thematic research group, addresses the big macro topics the risk of the global economy overheating given stimulus measures and the change in attitude of central banks towards employment goals. Then there is how tight labor markets may further boost inflation. A flow on is higher bond yields and the end of free money that has propped up markets since the financial crisis. As he notes, while "stock markets may not crash, they could witness the return of fundamental investing." It certainly would be welcomed even if it comes with the S&P several hundred/thousand point lower.

France has cancelled its order for Merck & Co''s Covid-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer''s competing drug before the end of January, the health minister said on Wednesday.

WUHAN: This photo taken on Tuesday shows a health worker collecting samples to be tested for COVID-19 at an ice and snow theme park. —AFP By B Izzak & Agencies KUWAIT: The health ministry yesterday reported 12 more cases of the COVID-19 Omicron variant in people arriving from several European countries, as a committee overseeing health conditions called for strictly imposing coronavirus precautionary measures. Health Ministry Spokesman Dr Abdullah Al-Sanad said the new cases have been isolated, adding the ministry has taken all necessary precautionary measures and launched an investigation into the cases. Dr Sanad stressed the need to implement home quarantine for all passengers arriving in Kuwait and strictly implementing health measures and other preventive procedures. He called on public to complete their vaccinations including the third booster dose, avoid unsafe gatherings, observe safe distances and continue sanitizing hands. He also advised the public to take seasonal winter vaccinations.

New Data Show Omicron Hospital Risk Significantly Lower Than Delta, FDA Approves Pfizer COVID Pill Just before the FDA announced that it had officially approved Pfizer''s COVID pill for to patients age 12 and older (though the drug will likely only be used in more high-risk patients), new data arrived from both South Africa and Scotland showing the hospitalization risk from omicron is significantly lower than from delta. Preliminary data from a Scotland study suggested the the newer variant is 2/3rds as likely to send somebody to the hospital. They did, however, warn that the variant could cause other issues due to its heightened infectiousness. The Scotland study drew on the health records of 5.4M people in Scotland. A separate study published online by researchers at South Africa’s National Institute for Communicable Diseases - who have been releasing breadcrumb trails of data about omicron since first confirming its existence with the WHO. Similarly found people infected with Omicron were 70% to 80% less likely to need hospital treatment than people infected with earlier variants, including Delta.

DUBLIN--(BUSINESS WIRE)--The "Polymerase Chain Reaction Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The polymerase chain reaction market was valued at approximately USD 5,170.37 million in 2020, and it is expected to reach USD 8,094 million by 2026, registering a CAGR of 7.83% during the forecast period, 2021-2026. Companies Mentioned Abbott Laboratories Agilent Technologies Inc. Becton, Dickinson and Company

Greatmark Investment Partners Inc. lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 5.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,788 shares of the companys stock after selling 300 shares during the quarter. Greatmark Investment Partners Inc.s holdings in Merck []

The Food and Drug Administration on Wednesday authorized Pfizer''s antiviral pill for the treatment of individuals at high risk of severe illness from COVID-19. Why it matters: At-home COVID-19 treatments, especially Pfizer''s Paxlovid, are seen as possible game-changers for the pandemic. The emergency use authorization comes as the U.S. sees a surge in new COVID-19 cases and hospitalizations largely driven by the Omicron variant. Driving the news: Pfizer released new data last week confirming Paxlovid reduced the risk of hospitalization or death by 89% in high-risk adults, Axios'' Tina Reed reports . An interim analysis of a second study of the pill that has so far shown a 70% reduction in hospitalization among standard-risk adults, Pfizer said. Pfizer also believes the Paxlovid treatment will work well against the Omicron variant because of the way the drug works. What they''re saying: " Todays authorization of PAXLOVID represents another tremendous example of how science will help us ultimately defeat this pandemic, which, even two years in, continues to disrupt and devastate lives across the world," Pfizer chairman and CEO Albert Bourla said in a statement. "This breakthrough therapy will change the way we treat COVID-19, and hopefully help reduce some of the significant pressures facing our healthcare and hospital systems," he added.

Magnolia Capital Management Ltd. bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,400 shares of the companys stock, valued at approximately $631,000. Other institutional investors and hedge []